Abstract: An antibody-drug conjugate, and a preparation method therefor and a use thereof are provided. A hydrophilic linker in the conjugate can satisfy linking of most active molecules. Moreover, the antibody-drug conjugate has good stability, hydrophilicity, and pharmacokinetic properties. The antibody-drug conjugate can be used in pharmaceutical compositions and can b used in treating cancers.

Abstract: Provided in the present application is an anti-Siglec 15 antibody or an antigen-binding fragment thereof, a pharmaceutical composition and immunoconjugate comprising the antibody or antigen-binding fragment, a nucleic acid molecule encoding the antibody or antigen-binding fragment thereof, a vector comprising the nucleic acid molecule, a host cell comprising the vector, a method for preparing the antibody or antigen-binding fragment, and the biological medical use of the antibody or antigen-binding fragment. The use comprises regulating the immune response, reversing the inhibition of the Siglec15 protein on PBMC lymphocyte proliferation or treating tumors associated with abnormal Siglec 15 expression.

Abstract: A novel anti-CD73 antibody and use thereof are provided. The anti-CD73 antibody can be used for treating tumors, particularly tumors expressing CD73 (CD73+) on the surface of tumor cells.

Abstract: Disclosed are an anti-human PVRIG antibody or an antigen-binding fragment thereof, as well as an application thereof in the preparation of a medicament for treating diseases, such as cancer, which are related to the abnormal expression of PVRIG.

Abstract: Provided in the present application is an anti-Siglec 15 antibody or an antigen-binding fragment thereof, a pharmaceutical composition and immunoconjugate comprising the antibody or antigen-binding fragment, a nucleic acid molecule encoding the antibody or antigen-binding fragment thereof, a vector comprising the nucleic acid molecule, a host cell comprising the vector, a method for preparing the antibody or antigen-binding fragment, and the biological medical use of the antibody or antigen-binding fragment. The use comprises regulating the immune response, reversing the inhibition of the Siglec15 protein on PBMC lymphocyte proliferation or treating tumors associated with abnormal Siglec 15 expression.